Impact of family support improvement behaviors on anti diabetic medication adherence and cognition in type 2 diabetic patients

Journal of Diabetes & Metabolic Disorders

Gholamhossein Mahmoudirad²  Mohsen Hassanabadi²  Mohsen Khoshniat Nikoo¹  Farah Madarshahian²  Hamidreza Khosravizade Tabasi² 

[1] Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, North Kargar Street, Tehran 1411413137, Iran;Birjand University of Medical Sciences, Ghafary Ave., Birjand 9717853577, Iran

关键词: Cognition disorder;    Medication adherence;    Family support;    Diabetes mellitus type 2;   

Others  :  1135842
DOI  :  10.1186/s40200-014-0113-2

 received in 2014-02-13, accepted in 2014-11-11,  发布年份 2014

【 摘 要 】

Background

Glycaemic control is the main goal of treatment for type 2 diabetic patients. Hyperglycaemia may result in cognitive decline. More family support may increase medication adherence and decrease glycaemic level. The purpose of this study was to determine the impact of family support improvement behavior on anti diabetic medication adherence and cognition in type 2 diabetic patients.

Method

The randomized control trial study was conducted on 91 patients from an outpatient diabetes clinic. They were randomly divided to intervention (n = 45) and control (n = 46) group. Data on the patients’ demographic information and their family gathered using a questionnaire, For two groups Morisky Medication Adherence Scale (MMAS), drug administration part of Diabetes Social Support Questionnaire – family version (DSSQ), Number Connection Test (NCT) were applied and hemoglobin A1C was measured two times in the onset of study and three months later for control group and before and after intervention for intervention group. The key family members of the intervention group were taught according to their educational needs in small groups.

Result

In intervention group mean of NCT score was significantly decreased after intervention (P = 0.006) however in the control group there was no significant difference after three months. In intervention group a significant correlation was noted between DSSQ scores and MMAS scores after intervention(r =0.67, P < 0.001) but, there was no significant correlation in the control group.

Conclusion

Family support instruction based on the educational needs of family members, may improve medication adherence through direct effect and cognitive status with indirect effect.

【 授权许可】

   
2014 Khosravizade Tabasi et al.; licensee BioMed Central.

【 参考文献 】

• [1]Tiv M, Viel JF, Mauny F, Eschwège E, Weill A, Fournier C, Fagot-Campagna A, Penfornis A: Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study. PLoS One 2012, 7:e32412.
• [2]Azizi F: Diabetes mellitus in the Islamic Republic of Iran. IDF bulletin 1996, 41:38-39.
• [3]Berger JE, Ahmann AJ, Balfour DC, Owens GS, Beltran R, Bush MA, Culpepper L, Owens GS, Ringel M, Welty FK: Treating to target: implementing an effective diabetes care paradigm for managed care. Am J Manag Care 2010, 16:S4-S35.
• [4]Liebl A, Mata M, Eschwage E: Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002, 45:S23-S28.
• [5]Massi-Benedetti M: The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002, 45:S1-S4.
• [6]Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
• [7]Tokuyama Y, Ishizuka T, Matsui K, Egashira T, Kanatsuka A: Predictors of glycemic control in Japanese subjects with type 2 diabetes mellitus. Metabolism 2008, 57:453-457.
• [8]Larsen PR, Kronenberg HM, Melmed S, Polonsky KS: Williams text book of endocriniligy. W.B Sunders, Philadelphia; 2003.
• [9]Norris SL, Engelgau MM, Narayan KM: Effectiveness of self-management. Training in type 2 diabetes. Diabetes Care 2001, 24:561-587.
• [10]Strachan MW, Deary IJ, Ewing F, Frier BM: Is type II diabetes associated with an increase risk of cognitive dysfunction? a critical review of published studies. Diabetes Care 1997, 20:433-445.
• [11]Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ: Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors. Diabetes Care 2009, 32:221-226.
• [12]Yamazaki Y, Miwa T, Sakurai H, Hanyu H, Iwamoto T, Odawara M: Clinical backgrounds and morbidity of cognitive impairment in elderly diabetic patients. Endocr J 2011, 58:109-115.
• [13]Coker LH, Shomaker SA: type 2 diabetes mellitus and cognition an under studied issue in womenshealths. J Psychosom Res 2003, 54:129-139.
• [14]Vinik A: Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007, 29:1236-1253.
• [15]Williams JLS, Walker RJ, Smalls BL, Campbell JA, Egede LE: Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. Diabetes Management 2014, 4:29-48.
• [16]Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM: The impact of cognitive function on medication management: Three studies. Health Psychol 2010, 29:50-55.
• [17]DiMatteo RM: Variations in patients adherence to medical recommendation: a quantitative review of 50 years of research. Med Care 2005, 42:200-209.
• [18]Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM: Adherence in chronic disease. Annu Rev Nurs Res 2000, 18:48-90.
• [19]Fisher L, Weihs KL: Can addressing family relationship improve outcomes in chronic disease? Report of the National Working Group on family- Based Interventions in Chronic Disease. J Fam Pract 2000, 49:561-566.
• [20]Mayberry LS, Osborn CY: Family support, medication adherence, and glycemic control among adults with type 2 diabetes. Diabetes Care 2012, 35(6):1239-1245.
• [21]García-Huidobro D, Bittner M, Brahm P, Puschel K: Family intervention to control type 2 diabetes: a controlled clinical trial. Fam Pract 2011, 28:4-11.
• [22]Bailey GR, Barner JC, Weems JK, Leckbee G, Solis R, Montemayor D, Pope ND: Assessing Barriers to Medication Adherence in Underserved Patients With Diabetes in Texas. Diabetes Educ 2012, 38:271-279.
• [23]Haidari S, Salahshourian A, Rafii F: The relationship between social support and quality of life in cancer patients. MSc thesis, IranUniversity of Medical Sciences; 2006.
• [24]Morisky DE, Ang A, Krousel-Wood M, Ward HJ: Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008, 10:348-354.
• [25]Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P: New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009, 15:59-66.
• [26]Reitan RM: The relation of the trail making test to organic brain damage. J Consult Psychol 1955, 19:393-394.
• [27]Reitan RM: Validity of the trail making test as on indicator of organic brain damage. Percept Mot Skills 1958, 8:271-276.
• [28]Glasgow RE, Toobert D: Social environment and regimen adherence among type II diabetic patients. Diabetes Care 1988, 11:377-386.
• [29]Wen LK, Shepard MD, Parchman ML: Family support, diet and exercise among older Mexican Americans with type 2 diabetes. Diabetes Educ 2004, 30:980-993.
• [30]Karlsen B, Idsoe T, Hanestad BR, Murberg T, Bru E: Perceptions of support, diabetes-related coping and psychological well-being in adults with type 1 and type 2 diabetes. Psychology Health Med 2004, 9:53-70.
• [31]Fisher L, Chelsa C, Bartz RJ, Gilliss C, Skaff MA, Sabogal F, Kanter RA, Lutz CP: The family and type 2 diabetes: a framework for intervention. Diabetes Educ 1998, 24:599-607.
• [32]Gonder-Frederick LA, Cox DJ, Ritterband LM: Diabetes and behavioural medicine: the second decade. J Consulting Clin Psychol 2002, 70:611-625.
• [33]White P, Smith SM, O’Dowd T: living with type 2 diabetes: a family perspective. Diabetic medication 2007, 24:796-801.
• [34]Trief PM, Grant W, Elbert K, Weinstock R: Family environment, glycaemic control and the psychosocial adaptation of adults with diabetes. Diabetes Care 1998, 21:241-245.
• [35]Ruggiero L, Prochaska JO: Readiness for change: application of the transtheoretical model to diabetes. Diabetes Spectrum 1993, 6:22-60.
• [36]Osborn CY, Egede LE: Validation of an information-motivation-behavioral skills model of diabetes self-care (IMB-DSC). Patient Educ Couns 2010, 79:49-54.
• [37]Tang TS, Brown MB, Funnell MM, Anderson RM: Social support, quality of life, and self-care behaviors among African Americans with type 2 diabetes. Diabetes Educ 2008, 34:266-276.
• [38]Fisher L, Chesla CA, Skaff MM, Gilliss C, Mullan JT, Bartz RJ, Kanter RA, Lutz CP: The family and disease management in Hispanic and European-American patients with type 2 diabetes. Diabetes Care 2000, 23:267-272.
• [39]Scheurer D, Choudhry N, Swanton KA, Matlin O, Shrank W: Association between different types of social support and medication adherence. Am J Manag Care 2012, 18:e461-e467.
• [40]Keogh KM, Smith SM, White P, McGilloway S, Kelly A, Gibney J, O’Dowd T: Psychological family intervention for poorly controlled type 2 diabetes. Am J Manag Care 2011, 17:105-113.
• [41]Strachan MW, Reynolds RM, Marioni RE, Price JF: Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011, 7:108-114.
• [42]Ryan CM, Geckle M: Why is learning and memory dysfunction in Type 2 diabetes limited to older adults? Diabetes Metab Res Rev 2000, 16:308-315.
• [43]Keogh KM, White P, Smith SM, McGilloway S, O’Dowd T, Gibney J: Changing illness perceptions in patients with poorly controlled type 2 diabetes, a randomised controlled trial of a family-based intervention: protocol and pilot study. BMC Fam Pract 2007, 8:36. BioMed Central Full Text